» Articles » PMID: 21248066

Convalescent Plasma Treatment Reduced Mortality in Patients with Severe Pandemic Influenza A (H1N1) 2009 Virus Infection

Abstract

Background: Experience from treating patients with Spanish influenza and influenza A(H5N1) suggested that convalescent plasma therapy might be beneficial. However, its efficacy in patients with severe pandemic influenza A(H1N1) 2009 virus (H1N1 2009) infection remained unknown.

Methods: During the period from 1 September 2009 through 30 June 2010, we conducted a prospective cohort study by recruiting patients aged ≥ 18 years with severe H1N1 2009 infection requiring intensive care. Patients were offered treatment with convalescent plasma with a neutralizing antibody titer of ≥ 1:160, harvested by apheresis from patients recovering from H1N1 2009 infection. Clinical outcome was compared with that of patients who declined plasma treatment as the untreated controls.

Results: Ninety-three patients with severe H1N1 2009 infection requiring intensive care were recruited. Twenty patients (21.5%) received plasma treatment. The treatment and control groups were matched by age, sex, and disease severity scores. Mortality in the treatment group was significantly lower than in the nontreatment group (20.0% vs 54.8%; P =  .01). Multivariate analysis showed that plasma treatment reduced mortality (odds ratio [OR], .20; 95% confidence interval [CI], .06-.69; P =  .011), whereas complication of acute renal failure was independently associated with death (OR, 3.79; 95% CI, 1.15-12.4; P =  .028). Subgroup analysis of 44 patients with serial respiratory tract viral load and cytokine level demonstrated that plasma treatment was associated with significantly lower day 3, 5, and 7 viral load, compared with the control group (P <  .05). The corresponding temporal levels of interleukin 6, interleukin 10, and tumor necrosis factor α (P <  .05) were also lower in the treatment group.

Conclusions: Treatment of severe H1N1 2009 infection with convalescent plasma reduced respiratory tract viral load, serum cytokine response, and mortality.

Citing Articles

Efficacy of convalescent plasma in hospitalized COVID-19 patients: findings from a controlled trial.

Costa T, Aoki M, Ribeiro C, Socca E, Itinose L, Basso R Braz J Med Biol Res. 2024; 57:e13627.

PMID: 39383382 PMC: 11463911. DOI: 10.1590/1414-431X2024e13627.


Estimates of actual and potential lives saved in the United States from the use of COVID-19 convalescent plasma.

Dragotakes Q, Johnson P, Buras M, Carter R, Joyner M, Bloch E Proc Natl Acad Sci U S A. 2024; 121(41):e2414957121.

PMID: 39352932 PMC: 11474081. DOI: 10.1073/pnas.2414957121.


Convalescent anti-SARS-CoV-2 plasma for the treatment of patients with COVID-19: a retrospective study RESCOVID-19.

Bohonek M, Maca J, Sagan J, rezac D, Fridrich V, Burantova A Virol J. 2024; 21(1):239.

PMID: 39350163 PMC: 11443855. DOI: 10.1186/s12985-024-02475-y.


The role of convalescent plasma and hyperimmune immunoglobulins in the COVID-19 pandemic, including implications for future preparedness.

So-Osman C, Burnouf T, Al-Riyami A, Bloch E, Estcourt L, Goel R Front Immunol. 2024; 15:1448720.

PMID: 39315108 PMC: 11416983. DOI: 10.3389/fimmu.2024.1448720.


Convalescent Plasma as Adjunctive Therapy for Hospitalized Patients with COVID-19: The Co-CLARITY Trial.

Gauiran D, Dumagay T, Ang M, Dungog C, Climacosa F, Maganito S Acta Med Philipp. 2024; 58(2):5-15.

PMID: 38966161 PMC: 11219538. DOI: 10.47895/amp.vi0.4903.


References
1.
Davies A, Jones D, Bailey M, Beca J, Bellomo R, Blackwell N . Extracorporeal Membrane Oxygenation for 2009 Influenza A(H1N1) Acute Respiratory Distress Syndrome. JAMA. 2009; 302(17):1888-95. DOI: 10.1001/jama.2009.1535. View

2.
Subramony H, Lai F, Ang L, Cutter J, Lim P, James L . An epidemiological study of 1348 cases of pandemic H1N1 influenza admitted to Singapore Hospitals from July to September 2009. Ann Acad Med Singap. 2010; 39(4):283-8. View

3.
Luke T, Kilbane E, Jackson J, Hoffman S . Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?. Ann Intern Med. 2006; 145(8):599-609. DOI: 10.7326/0003-4819-145-8-200610170-00139. View

4.
Lau S, Chan K, Yip C, Ng T, Tsang O, Woo P . Confirmation of the first Hong Kong case of human infection by novel swine origin influenza A (H1N1) virus diagnosed using ultrarapid, real-time reverse transcriptase PCR. J Clin Microbiol. 2009; 47(7):2344-6. PMC: 2708524. DOI: 10.1128/JCM.00924-09. View

5.
Birnkrant D, Cox E . The Emergency Use Authorization of peramivir for treatment of 2009 H1N1 influenza. N Engl J Med. 2009; 361(23):2204-7. DOI: 10.1056/NEJMp0910479. View